EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial

Manfred Welslau, Karin Potthoff, Matthias Zaiss, Lothar Müller, Cosima Brucker, Christoph Salat, Michael Untch, Johannes Meiler, Diana Lüftner, Anja Welt, Steffen Dörfel, Volker Hagen und 8 weitere

Oncology Research and Treatment · 2024

DOI: 10.1159/000542459 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Manfred Welslau und 19 weiteren Autor:innen. Beteiligte Einrichtung: Klinikum Aschaffenburg-Alzenau, Medizinische Klinik IV, Hämatologie/Onkologie, Aschaffenburg, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.

Methods

The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2− breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), safety, and quality of life. Data were analyzed with descriptive statistics.

Results

Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n = 157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n = 219), PFS was 20.1 months (95% CI 14.6–24.0), and OS was 40.9 months (95% CI 35.1–49.2). The most common grade 3/4 adverse event was neutropenia (33.4% n = 77). There were no treatment-related deaths.

Conclusion

The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFulvestrantMiddle AgedPyridinesGermanyErb-b2 Receptor Tyrosine KinasesAgedPiperazinesAromatase InhibitorsAdultReceptors, EstrogenProspective StudiesReceptors, ProgesteroneLetrozoleAged, 80 and overTreatment OutcomeQuality of LifeAndrostadienes

Stichwörter der Autor:innen

AnastrozoleEndocrine therapyExemestaneFulvestrantLetrozolePalbociclib

Substanzen

FulvestrantPyridinesErb-b2 Receptor Tyrosine KinasesPiperazinesAromatase InhibitorsReceptors, EstrogenReceptors, ProgesteroneLetrozoleAndrostadienespalbociclib

Autor:innen und Institutionen

  • Klinikum Aschaffenburg-Alzenau, Medizinische Klinik IV, Hämatologie/Onkologie, Aschaffenburg, Germany.
  • Medical Department, iOMEDICO, Freiburg, Germany.
  • Praxis für interdisziplinäre Onkologie and Hämatologie, Freiburg, Germany.
  • Onkologie UnterEms, Leer-Emden-Papenburg, Leer, Germany.
  • Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Klinikum Nürnberg, Nuremberg, Germany.
  • Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH, Ärztehaus Nymphenburg, Munich, Germany.

Zitieren

APA

Welslau, M., Potthoff, K., Zaiss, M., Müller, L., Brucker, C., Salat, C., Untch, M., Meiler, J., Lüftner, D., Welt, A., Dörfel, S., Hagen, V., Stein, A., Liersch, R., Kuhn, T., Siebenbach, H. U., Bing, G., Vannier, C., Marschner, N., & Gratzke, K. (2024). Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial. Oncology Research and Treatment. https://doi.org/10.1159/000542459

Vancouver

Welslau M, Potthoff K, Zaiss M, Müller L, Brucker C, Salat C, et al. Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial. Oncology Research and Treatment. 2024. doi:10.1159/000542459

BibTeX
@article{Welslau2024,
  author = {Welslau, Manfred and Potthoff, Karin and Zaiss, Matthias and Müller, Lothar and Brucker, Cosima and Salat, Christoph and Untch, Michael and Meiler, Johannes and Lüftner, Diana and Welt, Anja and Dörfel, Steffen and Hagen, Volker and Stein, Alexander and Liersch, Rüdiger and Kuhn, Thomas and Siebenbach, Hans Ulrich and Bing, Gerlinde and Vannier, Corinne and Marschner, Norbert and Gratzke, Katja},
  title = {Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000542459}
}
Kostenlos starten →